Kiromic BioPharma EBITDA 2011-2026 | KRBP

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Kiromic BioPharma

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-21.5 M	-17.7 M	-29.4 M	-25.3 M	-19.2 M	-3.62 M	-3.1 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-3.1 M	-29.4 M	-17.1 M

Quarterly EBITDA Kiromic BioPharma

2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-6.05 M	-5.8 M	-	-4.99 M	-3.74 M	-4.22 M	-	-7.86 M	-8.03 M	-7.18 M	-	-6.01 M	-4.87 M	-3.86 M	-	-2.37 M	-11.3 M	-1.82 M	-	-859 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-859 K	-11.3 M	-5.27 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
ACADIA Pharmaceuticals ACAD	232 M	$ 22.56	2.13 %	$ 3.74 B	USA
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
argenx SE ARGX	-349 M	$ 785.07	2.57 %	$ 25 B	Niderland
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Akebia Therapeutics AKBA	24.8 M	$ 1.43	3.62 %	$ 368 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Allakos ALLK	-190 M	-	-	$ 28.6 M	USA
Alnylam Pharmaceuticals ALNY	557 M	$ 327.25	2.42 %	$ 42.9 B	USA
AlloVir ALVR	-46.1 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
Alterity Therapeutics Limited ATHE	-17.3 M	$ 3.9	3.7 %	$ 9.38 B	Australia
Autolus Therapeutics plc AUTL	-262 M	$ 1.49	9.56 %	$ 397 M	Britain
AVROBIO AVRO	10.8 M	-	1083.1 %	$ 745 M	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Amphastar Pharmaceuticals AMPH	172 M	$ 20.4	-0.87 %	$ 954 M	USA
Aquestive Therapeutics AQST	-70.5 M	$ 4.18	1.21 %	$ 447 M	USA
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	-2.45 M	$ 2.66	3.5 %	$ 16.7 M	USA
AstraZeneca PLC AZN	1.06 B	-	-	$ 96.9 B	Britain
Brainstorm Cell Therapeutics BCLI	-9.75 M	-	-2.5 %	$ 5.88 M	USA
Arcutis Biotherapeutics ARQT	-11.5 M	$ 24.61	5.76 %	$ 3.13 B	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
BeiGene, Ltd. BGNE	589 M	-	0.49 %	$ 251 B	Cayman-islands
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Cabaletta Bio CABA	-171 M	$ 3.09	0.65 %	$ 310 M	USA
CymaBay Therapeutics CBAY	-101 M	-	-	$ 3.45 B	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Codiak BioSciences CDAK	-64.2 M	-	-55.98 %	$ 2.15 M	USA
Avid Bioservices CDMO	-7.57 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	-176 M	-	-	$ 1.41 B	USA
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Celldex Therapeutics CLDX	-284 M	$ 32.41	3.38 %	$ 2.15 B	USA
Celsion Corporation CLSN	-14.4 M	-	-6.63 %	$ 13.9 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Chimerix CMRX	-93 M	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	-76 M	-	-	$ 401 M	USA
Akari Therapeutics, Plc AKTX	-21.6 M	$ 3.88	2.11 %	$ 261 B	Britain